A critical systematic review of extracellular vesicle clinical trials
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
This systematic review examines the landscape of extracellular vesicle (EV)‐related clinical trials to elucidate the field's trends in clinical applications and EV‐related methodologies, with an additional focus on the acknowledgement of EV subpopulations. By analysing data from public reporting repositories, we catalogued 471 EV‐related clinical trials to date, with indications for over 200 diseases. Diagnostics and companion diagnostics represented the bulk of EV‐related clinical trials with cancer being the most frequent application. EV‐related therapeutics trials mainly utilized mesenchymal stromal cell (MSC) EVs and were most frequently used for treatment of respiratory illnesses. Ultracentrifugation and RNA‐sequencing were the most common isolation and characterization techniques; however, methodology for each was not frequently reported in study records. Most of the reported characterization relied on bulk characterization of EV isolates, with only 11% utilizing EV subpopulations in their experimental design. While this may be connected to a lack of available techniques suitable for clinical implementation, it also highlights the opportunity for use of EV subpopulations to improve translational efforts. As academic research identifies more chemically distinct subpopulations and technologies for their enrichment, we forecast to more refined EV trials in the near future. This review emphasizes the need for meticulous methodological reporting and consideration of EV subpopulations to enhance the translational success of EV‐based interventions, pointing towards a paradigm shift in personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 2×
“This lack of specification is in stark contrast to the research field where there has been a large effort to increase reporting of many of these parameters, as evidenced by MISEV reports (Théry et al., 2018; Welsh et al., 2024).”
BackgroundResultTumour exosome integrins determine organotropic metastasis
Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature · doi:10.1038/nature15756 · Cited by 5,101
Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12404 · Cited by 4,663
Self-citationKowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730 · cited 1×
“Alongside this inherent heterogeneity, exogenous factors can also lead to changes in EV physical characteristics and function such as isolation technique (Veerman et al., 2021), storage conditions (Gelibter et al., 2022), and route of administration (Kang et al., 2021; Wiklander et al., 2015).”
BackgroundEV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
EV-TRACK Consortium, Van Deun, J., Mestdagh, P., Agostinis, P., Akay, Ö., Anand, S., Anckaert, J., Martinez, Z. A., Baetens, T., Beghein, E., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4185 · Cited by 1,284 · cited 1×
“…is still identifying some of the factors that impact EV characteristics and function, there has been a great push for rigorous record keeping of EV related protocols to ensure that these factors are controlled and chosen purposefully (Théry et al., 2018; Van Deun et al., 2017; Welsh et al., 2024).”
BackgroundFong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., Chow, A., O’Connor, S. T. F., Li, S., Chin, A. R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3094 · Cited by 1,118
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737 · cited 1×
“Moreover, EVs can be further engineered and tailored for particular functions, such as loading of exogenous cargo or theranostic payloads (Cheng & Hill, 2022; Escudé Martinez de Castilla et al., 2021).”
BackgroundBanks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124407 · Cited by 561
Physical exercise induces rapid release of small extracellular vesicles into the circulation
Frühbeis, C., Helmig, S., Tug, S., Simon, P., & Krämer‐Albers, E. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.28239 · Cited by 360 · cited 1×
“EV heterogeneity can also evolve in vivo as a result of changing disease status and metabolic stressors based on age (Eitan et al., 2017), sex (Enjeti et al., 2017), recent exercise (Frühbeis et al., 2015), and more.”
BackgroundZhuang, X., Teng, Y., Samykutty, A., Mu, J., Deng, Z., Zhang, L., Cao, P., Rong, Y., Yan, J., Miller, D., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.188 · Cited by 294 · cited 2×
“…et al., 2020), ginger (Li et al., 2018; Zhang et al., 2016), ginseng (Cao et al., 2019), grape (Ju et al., 2013), grapefruit (Savcı et al., 2021; Zhuang et al., 2016), and many others have been reported to exhibit therapeutic effects in many contexts, including cancer (Cao et al., 2019;…”
Background
Metadata
- Authors
- Mizenko, R. R., Feaver, M., Bozkurt, B. T., Lowe, N., Nguyen, B., Huang, K., Wang, A., & Carney, R. P.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2024-09-27
- Volume
- 13
- Issue
- 10
- Pages
- e12510-e12510
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W4402922347
- Cited by
- 185
- References
- 12
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.